Knowledge at the heart of leadership
Welcome to Liftstream - Life Sciences Recruitment

Liftstream is an executive search recruitment company in the life sciences sector

Dimension Therapeutics Diversifies Leadership with Management and Board Appointment

Dimension Therapeutics, a leading rare disease company advancing novel, liver-directed treatments for diverse genetic disorders has announced that it has expanded its Board of Directors with the elections of Georges Gemayel, Ph.D., former Executive Vice President of Genzyme Corporation, and Arlene M. … Continue reading

Posted in Executive Appointments, Orphan Drugs and Rare Diseases | Tagged , , , , , , , , , , , , , , , , , , | Leave a comment

Hans Schikan appointed Chairman of Complix

Complix, a biopharmaceutical company focused on developing a pipeline of transformative protein therapeutics, called Alphabodies™, mainly focused on oncology and autoimmune diseases, today announced the appointment of Hans Schikan as Chairman of its Board of Directors.   Hans Schikan has more than … Continue reading

Posted in Executive Appointments | Tagged , , , , , , , , , , , , , , , | Leave a comment

Wilson Therapeutics appoints Chief Medical Officer

Fresh from announcing that Hans Schikan, ex-CEO of Prosensa, would be joining the Board of Directors at Wilson Therapeutics, the company have announced the appointment of another Genzyme allumni, Dr. Carl Bjartmar as chief medical officer (CMO). Dr. Bjartmar will … Continue reading

Posted in Executive Appointments | Tagged , , , , , , , , , , , | Leave a comment

Prosensa announces senior management and board appointments

Authored by Karl Simpson Prosensa HoldingsN.V, the drug development company focused on advancing therapies for duchenne muscular dystrophy announced the appointment of Willem W. van Weperen to the new position of chief commercial officer and the addition of Dr. Annalisa Jenkins … Continue reading

Posted in Executive Appointments, Orphan Drugs and Rare Diseases, Recruitment Market | Tagged , , , , , , , , , , , , | Leave a comment

Sanofi appoint Chief Patient Officer

Authored by James Sheppard The French pharmaceutical giant Sanofi recently announced that it had appointed Dr Anne C. Beal as its new Chief Patient Officer. This is a new role within Sanofi and one that the company hopes will increase … Continue reading

Posted in Executive Appointments, Pharmaceutical business, Recruitment Market | Tagged , , , , , , , , , , , , , | Leave a comment

Fidelity Biosciences and REGENX launch new gene therapy company

Authored by James Sheppard The US based venture capital company Fidelity Bioscience has partnered with biotechnology firm REGENX to launch a new company utlising adeno-associated virus (AAV) gene therapy. The company will have access to world class technology and development … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , , , , | Leave a comment

Osiris sells stem cell business in $100m deal

Authored by James Sheppard The US based biotechnology company Osiris Therapeutics has announced a $100m deal with Australian biotech Mesoblast for the company to buy its stem cell platform. The deal includes Osiris’s off the shelf stem cell product Prochymal. … Continue reading

Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , | Leave a comment

Academic and industry partnerships drive new Gene Therapy push

Authored by James Sheppard There are many areas of pharmaceutical innovation currently receiving considerable attention, both for their scientific potential in a personalised medicine era but equally because of the potential they offer to investors. Gene Therapy is one such … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Massachusetts biotech continues to excite with new investments

Authored by Karl Simpson Massachusetts is a booming biotech cluster and this week has seen a number of funding events that once again signal the level of innovation and investor interest the cluster attracts. First up, David Mott’s New Enterprise … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Isis gains milestone from GSK for rare disease trial and Aegerion takes them on in HoFH

Authored by Karl Simpson Isis Pharmaceuticals is developing a drug for the treatment of the rare diseases transthyretin amyloidosis. The disease is a severe and rare genetic disorder characterized by dysfunction of the peripheral nerve and/or heart tissues. The company … Continue reading

Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , | Leave a comment




Contact Us

   Liftstream Ltd.
67 Grosvenor Street
London
W1K 3JN

   Tel: ​+44 (0)20 3178 5864
   info@liftstream.com

Register your CV

Apply for sector specific vacancies or request a confidential discussion



Registered in England No: 5009233
VAT: 843679292

Follow Us





Sitemap